HRP20150997T1 - Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera - Google Patents
Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera Download PDFInfo
- Publication number
- HRP20150997T1 HRP20150997T1 HRP20150997TT HRP20150997T HRP20150997T1 HR P20150997 T1 HRP20150997 T1 HR P20150997T1 HR P20150997T T HRP20150997T T HR P20150997TT HR P20150997 T HRP20150997 T HR P20150997T HR P20150997 T1 HRP20150997 T1 HR P20150997T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvent
- kda
- molecular weight
- copolymer material
- plg
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 229920001577 copolymer Polymers 0.000 claims 12
- 239000000463 material Substances 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000012867 bioactive agent Substances 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000010195 Onychomycosis Diseases 0.000 claims 2
- 201000005882 tinea unguium Diseases 0.000 claims 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- HNPFPERDNWXAGS-LZCJLJQNSA-N (e)-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]hept-5-enoic acid Chemical compound C=1C=CC=CC=1CCC(O)CCC1C(O)CC(O)C1C\C=C\CCCC(O)=O HNPFPERDNWXAGS-LZCJLJQNSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960003679 brimonidine Drugs 0.000 claims 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 1
- 229960000722 brinzolamide Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 238000000151 deposition Methods 0.000 claims 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims 1
- 229960003933 dorzolamide Drugs 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 210000004905 finger nail Anatomy 0.000 claims 1
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229960002700 octreotide Drugs 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 1
- 229960002722 terbinafine Drugs 0.000 claims 1
- 210000004906 toe nail Anatomy 0.000 claims 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/88—Post-polymerisation treatment
- C08G63/90—Purification; Drying
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
Claims (8)
1. Postupak pripreme biokompatibilnog, biorazgradivog, ne-hidroliziranog PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja za oblik s kontroliranim oslobađanjem s prosječnom molekulskom masom od 10 kilodaltona do 50 kilodaltona i indeksom polidisperznosti od 1.4-2.0 i iz kojeg se izdvaja uklonjena frakcija kopolimera naznačena prosječnom molekulskom masom od 4 kDa do 10 kDa i indeksom polidisperznosti od 1.4 do 2.5,
postupak obuhvaća
izdvajanje uklonjene frakcije kopolimera naznačenog prosječnom molekulskom masom od 4 kDa do 10 kDa i indeksom polidisperznosti od 1.4 do 2.5 iz početnog PLG kopolimernog materijala,
otapanje početnog PLG kopolimernog materijala u otapalu radi dobivanja otopine, zatim taloženje PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja dovođenjem u doticaj otopine s ne-otapalom i dobivanjem taloženog PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja,
postupak ne obuhvaća korak hidrolize PLG kopolimera veće molekulske mase.
2. Postupak prema zahtjevu 1, gdje se otapalo i ne-otapalo mogu pomiješati.
3. Postupak prema zahtjevu 1, gdje je otapalo diklorometan ili kloroform, ili gdje je ne-otapalo metanol ili etanol, ili oboje.
4. Postupak prema zahtjevu 1, gdje uklonjena frakcija kopolimera čini 2% do 20% težine, 3% do 15% težine, ili 5% do 10% težine početnog kopolimernog materijala.
5. Uporaba plovnog dostavnog sustava u obliku s kontroliranim oslobađanjem, plovni dostavni sustav obuhvaća biokompatibilni, biorazgradivi, ne-hidrolizirani PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja za kontrolirano oslobađanje, pripremljen prema postupku iz zahtjeva 1 i s prosječnom molekulskom masom od 10 kilodaltona do 50 kilodaltona i indeksom polidisperznosti od 1.4-2.0 i iz kojeg se izdvaja uklonjena frakcija kopolimera naznačena prosječnom molekulskom masom od 4 kDa do 10 kDa i indeksom polidisperznosti od 1.4 do 2.5, organsko otapalo, i
medicinski indicirano bioaktivno sredstvo
za liječenje stanja u bolesnika.
6. Uporaba prema zahtjevu 5, gdje se stanje izabire iz skupine koja obuhvaća rak prostate, akromegaliju, glaukom, neželjenu plodnost, bol, onikomikozu noktiju na nožnim prstima, onikomikozu noktiju na prstima ruku, bakterijsku infekciju, gljivičnu infekciju, virusnu infekciju, psihozu, malignost i imuni odgovor.
7. Uporaba prema zahtjevu 6, gdje se bioaktivno sredstvo izabire iz skupine koja obuhvaća antivirotik, steroid za kontrolu začeća, antibiotik, analgetik, antipsihotik, prostaglandin, inhibitor karbonske anhidraze, α-adrenergički antagonist i β-adrenergički antagonist.
8. Uporaba prema zahtjevu 6, gdje se bioaktivno sredstvo izabire iz skupine koja obuhvaća leuprolid, oktreotid, terbinafin, brimonidin, latanoprost, latanoprost kiselinu, travoprost, travoprost kiselinu, brinzolamid, dorzolamid, betaksolol, risperidon i rapamicin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90143507P | 2007-02-15 | 2007-02-15 | |
EP08725511.3A EP2115029B1 (en) | 2007-02-15 | 2008-02-13 | Low burst poly-(lactide/glycolide) and methods to produce polymers |
PCT/US2008/001887 WO2008100532A1 (en) | 2007-02-15 | 2008-02-13 | Low burst poly-(lactide/glycolide) and methods to produce polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150997T1 true HRP20150997T1 (hr) | 2015-12-18 |
Family
ID=39504385
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231117TT HRP20231117T3 (hr) | 2007-02-15 | 2008-02-13 | Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja |
HRP20150997TT HRP20150997T1 (hr) | 2007-02-15 | 2015-09-21 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera |
HRP20192055TT HRP20192055T1 (hr) | 2007-02-15 | 2019-11-14 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231117TT HRP20231117T3 (hr) | 2007-02-15 | 2008-02-13 | Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192055TT HRP20192055T1 (hr) | 2007-02-15 | 2019-11-14 | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i metode za proizvodnju polimera |
Country Status (16)
Country | Link |
---|---|
US (7) | US9187593B2 (hr) |
EP (3) | EP3660073B1 (hr) |
JP (3) | JP5342459B2 (hr) |
CA (1) | CA2678350C (hr) |
CY (2) | CY1116785T1 (hr) |
DK (3) | DK3202814T3 (hr) |
ES (3) | ES2755374T3 (hr) |
FI (1) | FI3660073T3 (hr) |
HK (1) | HK1138303A1 (hr) |
HR (3) | HRP20231117T3 (hr) |
HU (3) | HUE063170T2 (hr) |
LT (2) | LT3202814T (hr) |
PL (3) | PL2115029T3 (hr) |
PT (3) | PT3660073T (hr) |
SI (3) | SI3202814T1 (hr) |
WO (1) | WO2008100532A1 (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
US20070196416A1 (en) | 2006-01-18 | 2007-08-23 | Quest Pharmaceutical Services | Pharmaceutical compositions with enhanced stability |
SI3202814T1 (sl) | 2007-02-15 | 2019-12-31 | Tolmar Therapeutics, Inc. | Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov |
MX354603B (es) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
WO2009148580A2 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Controlled release copolymer formulation with improved release kinetics |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
ES2589106T3 (es) | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Composición inyectable antipsicótica de liberación controlada |
US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
CN103421172B (zh) * | 2012-05-23 | 2016-01-20 | 上海现代药物制剂工程研究中心有限公司 | 一种生物可降解聚酯的纯化工艺 |
CA2903769A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
WO2014168134A1 (ja) | 2013-04-11 | 2014-10-16 | 三井化学株式会社 | 乳酸―グリコール酸共重合体の製造法またはその塩の製造法 |
US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
US11000520B2 (en) | 2014-11-07 | 2021-05-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
CN112545995B (zh) * | 2018-05-16 | 2024-02-23 | 珠海市丽珠微球科技有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
ES2952213T3 (es) | 2020-02-06 | 2023-10-30 | Ocular Therapeutix Inc | Composiciones y métodos para tratar enfermedades oculares |
EP4221684A1 (en) | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer delivery system for extended delivery of testosterone |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
DE3641692A1 (de) | 1986-12-06 | 1988-06-09 | Boehringer Ingelheim Kg | Katalysatorfreie resorbierbare homopolymere und copolymere |
DE3708916A1 (de) | 1987-03-19 | 1988-09-29 | Boehringer Ingelheim Kg | Verfahren zur reinigung resorbierbarer polyester |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
ATE168391T1 (de) | 1990-04-13 | 1998-08-15 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung |
USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
US6353030B1 (en) * | 1990-08-01 | 2002-03-05 | Novartis Ag | Relating to organic compounds |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
DE69524398T2 (de) | 1994-04-08 | 2002-07-18 | Atrix Lab Inc | Flüssige mittel zur wirkstoffabgabe |
AU5004196A (en) | 1995-03-10 | 1996-10-02 | Boehringer Mannheim Gmbh | Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
JP4317599B2 (ja) | 1996-06-26 | 2009-08-19 | 武田薬品工業株式会社 | 徐放性製剤 |
IL135415A0 (en) | 1997-10-03 | 2001-05-20 | Macromed Inc | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
DE60118575T3 (de) | 2000-08-07 | 2011-05-19 | Takeda Pharmaceutical Co. Ltd. | Milchsäurepolymer und verfahren zu dessen herstellung |
TWI225416B (en) | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
JP5188670B2 (ja) | 2001-06-29 | 2013-04-24 | 武田薬品工業株式会社 | 徐放性組成物およびその製造法 |
US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
BRPI0516308A2 (pt) * | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
CA2586846C (en) * | 2004-11-10 | 2013-12-31 | Qlt Usa Inc. | A stabilized polymeric delivery system |
EP2079767B1 (en) * | 2006-10-11 | 2014-08-27 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
SI3202814T1 (sl) | 2007-02-15 | 2019-12-31 | Tolmar Therapeutics, Inc. | Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov |
-
2008
- 2008-02-13 SI SI200832098T patent/SI3202814T1/sl unknown
- 2008-02-13 LT LT15185218T patent/LT3202814T/lt unknown
- 2008-02-13 HR HRP20231117TT patent/HRP20231117T3/hr unknown
- 2008-02-13 DK DK15185218T patent/DK3202814T3/da active
- 2008-02-13 HU HUE19203071A patent/HUE063170T2/hu unknown
- 2008-02-13 HU HUE08725511A patent/HUE025842T2/en unknown
- 2008-02-13 SI SI200832213T patent/SI3660073T1/sl unknown
- 2008-02-13 PT PT192030716T patent/PT3660073T/pt unknown
- 2008-02-13 US US12/527,377 patent/US9187593B2/en not_active Expired - Fee Related
- 2008-02-13 WO PCT/US2008/001887 patent/WO2008100532A1/en active Application Filing
- 2008-02-13 EP EP19203071.6A patent/EP3660073B1/en active Active
- 2008-02-13 HU HUE15185218A patent/HUE047775T2/hu unknown
- 2008-02-13 DK DK19203071.6T patent/DK3660073T3/da active
- 2008-02-13 PT PT87255113T patent/PT2115029E/pt unknown
- 2008-02-13 EP EP08725511.3A patent/EP2115029B1/en active Active
- 2008-02-13 CA CA2678350A patent/CA2678350C/en not_active Expired - Fee Related
- 2008-02-13 EP EP15185218.3A patent/EP3202814B1/en active Active
- 2008-02-13 ES ES15185218T patent/ES2755374T3/es active Active
- 2008-02-13 DK DK08725511.3T patent/DK2115029T3/en active
- 2008-02-13 ES ES08725511.3T patent/ES2550014T3/es active Active
- 2008-02-13 PL PL08725511T patent/PL2115029T3/pl unknown
- 2008-02-13 ES ES19203071T patent/ES2956244T3/es active Active
- 2008-02-13 FI FIEP19203071.6T patent/FI3660073T3/fi active
- 2008-02-13 SI SI200831512T patent/SI2115029T1/sl unknown
- 2008-02-13 PL PL15185218T patent/PL3202814T3/pl unknown
- 2008-02-13 PL PL19203071.6T patent/PL3660073T3/pl unknown
- 2008-02-13 PT PT151852183T patent/PT3202814T/pt unknown
- 2008-02-13 JP JP2009550095A patent/JP5342459B2/ja active Active
- 2008-02-13 LT LTEP19203071.6T patent/LT3660073T/lt unknown
-
2010
- 2010-05-10 HK HK10104526.3A patent/HK1138303A1/xx unknown
-
2013
- 2013-08-09 JP JP2013166807A patent/JP5848290B2/ja active Active
-
2015
- 2015-04-10 JP JP2015080726A patent/JP6195587B2/ja active Active
- 2015-09-21 HR HRP20150997TT patent/HRP20150997T1/hr unknown
- 2015-10-08 CY CY20151100906T patent/CY1116785T1/el unknown
- 2015-10-27 US US14/924,243 patent/US9561282B2/en active Active
-
2016
- 2016-12-19 US US15/384,117 patent/US9655970B2/en active Active
-
2017
- 2017-04-18 US US15/490,615 patent/US9974824B2/en active Active
-
2018
- 2018-04-10 US US15/950,024 patent/US10206970B2/en active Active
-
2019
- 2019-01-08 US US16/242,316 patent/US11147880B2/en active Active
- 2019-11-14 HR HRP20192055TT patent/HRP20192055T1/hr unknown
- 2019-11-18 CY CY20191101209T patent/CY1122304T1/el unknown
-
2021
- 2021-09-16 US US17/477,361 patent/US11717572B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150997T1 (hr) | Poli-(laktid/glikolid) sa smanjenim efektom naglog oslobađanja i postupci proizvodnje polimera | |
JP2016094411A5 (hr) | ||
CN103374128B (zh) | 两亲性三嵌段共聚物、聚合物纳米载体制剂及制备方法 | |
JP6282231B2 (ja) | 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子 | |
CN107412168A (zh) | 含有水难溶性药物的缓释聚合物微粒及其制备方法 | |
JP2014511426A5 (hr) | ||
US10959954B2 (en) | Dexamethasone prodrug compositions and uses thereof | |
JP2015502957A5 (hr) | ||
JP2011521969A5 (hr) | ||
CN102634047B (zh) | 一种高分子水凝胶的制备方法 | |
US10682312B2 (en) | Method for preparation of hybrid amphiphilic star copolymer nano micelles | |
KR20110069093A (ko) | 비닐 알코올 코폴리머 크리오겔, 비닐 알코올 코폴리머, 및 이의 제조 방법 및 이로부터 제조된 산물 | |
JP2016504369A5 (hr) | ||
Yin et al. | Anticancer camptothecin-N-poly (lactic acid) nanoconjugates with facile hydrolysable linker | |
RU2016149734A (ru) | Направленно доставляемые терапевтические наночастицы и способы их получения и использования | |
Andonova | Synthetic polymer-based nanoparticles: Intelligent drug delivery systems | |
US20140086995A1 (en) | Polymer microsphere compositions for localized delivery of therapeutic agents | |
WO2015081830A1 (zh) | 多臂聚乙二醇硬脂酸衍生物和油酸衍生物 | |
Cai et al. | Recent development of polymer nanomicelles in the treatment of eye diseases | |
CN105362223B (zh) | 一种可靶向药物的三嵌段共聚物胶束的制备方法 | |
EP2081548A2 (en) | Compositions and methods for ph targeted drug delivery | |
JP2010504318A5 (hr) | ||
CN102225204A (zh) | 抗肿瘤的pH敏感缓释植入剂及制备方法 | |
CA3232086A1 (en) | Prodrugs of axitinib | |
CN102443166A (zh) | 醋酸双环胍催化开环共聚合合成乳酸-丝氨酸共聚物的工艺方法 |